Who is eligible for clinical trial NCT04135846?

Participants must meet protocol criteria for Alcohol Use Disorder (AUD). Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT04135846 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-03-18

Alpha-1 Blockade for Alcohol Use Disorder (AUD) (NCT04135846)

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Brown University

🩺 Plain-English Summary (8th-Grade Level)

The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (13 items).

Location: Brown University — Providence, Rhode Island

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Male or female, 18 years of age
Meet the DSM-5 criteria for AUD
Desire to reduce or quit alcohol drinking
Breath alcohol (BrAC) = 0.00 at each visit
In good health as confirmed by medical history, physical examination and lab tests
Willing to adhere to the study procedures
Understand informed consent and questionnaires in English at an 8th grade level

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Women who are breastfeeding or /positive urine test for pregnancy
CrCl\<60mL/min
Suicide attempt in the last three months
Current diagnosis of other substance disorder other than nicotine as assessed by self-report and urine toxicology screen at baseline
Current use of medication that may interact with doxazosin and/or yohimbine
History of allergy to any alpha receptor blockers
Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) score ≥ 8
Treatment with disulfiram, naltrexone, acamprosate, topiramate within 1 month prior to screening
Treatment with any alpha-blocker
Individuals with cardiac heat failure (CHF), as assessed by the medical history, the physical exam and the ECG.
Baseline hypotension defined as BP reading lower than 90/60 mmHg

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Brown University — Providence, Rhode Island

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗